Emmanuel Papadakis
Stock Analyst at Deutsche Bank
(1.85)
# 3,103
Out of 4,876 analysts
41
Total ratings
47.37%
Success rate
0.55%
Average return
Main Sectors:
Stocks Rated by Emmanuel Papadakis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintains: Buy | $95 → $150 | $106.39 | +40.99% | 9 | Sep 19, 2024 | |
| MRNA Moderna | Upgrades: Hold | $85 → $80 | $27.03 | +195.97% | 8 | Aug 6, 2024 | |
| GRFS Grifols | Downgrades: Sell | n/a | $8.85 | - | 2 | Mar 12, 2024 | |
| AZN AstraZeneca | Downgrades: Hold | n/a | $69.82 | - | 3 | Feb 8, 2024 | |
| ALVO Alvotech | Maintains: Hold | $8 → $12 | $9.20 | +30.43% | 2 | Mar 7, 2023 | |
| SNY Sanofi | Upgrades: Hold | n/a | $47.96 | - | 4 | Aug 12, 2022 | |
| NVO Novo Nordisk | Upgrades: Buy | n/a | $68.23 | - | 4 | Mar 16, 2022 | |
| CVAC CureVac | Initiates: Hold | $35 | $5.38 | +550.68% | 1 | Oct 22, 2021 | |
| NVS Novartis AG | Downgrades: Sell | n/a | $119.93 | - | 3 | Sep 20, 2021 | |
| ARGX argenx SE | Initiates: Hold | n/a | $562.27 | - | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $38.50 | - | 4 | Feb 4, 2021 |
BioNTech SE
Sep 19, 2024
Maintains: Buy
Price Target: $95 → $150
Current: $106.39
Upside: +40.99%
Moderna
Aug 6, 2024
Upgrades: Hold
Price Target: $85 → $80
Current: $27.03
Upside: +195.97%
Grifols
Mar 12, 2024
Downgrades: Sell
Price Target: n/a
Current: $8.85
Upside: -
AstraZeneca
Feb 8, 2024
Downgrades: Hold
Price Target: n/a
Current: $69.82
Upside: -
Alvotech
Mar 7, 2023
Maintains: Hold
Price Target: $8 → $12
Current: $9.20
Upside: +30.43%
Sanofi
Aug 12, 2022
Upgrades: Hold
Price Target: n/a
Current: $47.96
Upside: -
Novo Nordisk
Mar 16, 2022
Upgrades: Buy
Price Target: n/a
Current: $68.23
Upside: -
CureVac
Oct 22, 2021
Initiates: Hold
Price Target: $35
Current: $5.38
Upside: +550.68%
Novartis AG
Sep 20, 2021
Downgrades: Sell
Price Target: n/a
Current: $119.93
Upside: -
argenx SE
Jul 23, 2021
Initiates: Hold
Price Target: n/a
Current: $562.27
Upside: -
Feb 4, 2021
Downgrades: Sell
Price Target: n/a
Current: $38.50
Upside: -